• Kathleen A Lee, Niharika Ganta, Jay R Horton, and Emily Chai.
• 1 Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute , Boston, Massachusetts.
• J Palliat Med. 2016 Nov 1; 19 (11): 1179-1187.

BackgroundOpioids are the mainstay of pain control for patients with chronic pain. Often, opioids with reported active metabolites, such as morphine and hydromorphone, are thought to increase the risk of neurotoxicity in renal impairment.ObjectivesTo identify and assess the quality of evidence for neurotoxic effects in patients with renal impairment receiving morphine or hydromorphone.MethodsSystematic searches were conducted of the following databases from inception to December 2015: MEDLINE, CINAHL, EMBASE, in addition to hand-searching relevant review articles' citations. Studies were included if they reported neurotoxic effects of either morphine or hydromorphone for chronic or malignant pain in patients with renal impairment. Review articles and case reports were excluded. Narrative review was undertaken. The Grading of Recommendations, Assessment, Development and Evaluation approach was used to assess study quality.ResultsSix original articles, three prospective and three retrospective studies were identified and assessed. No relevant randomized clinical trials were identified.ConclusionsAlthough morphine and hydromorphone use may be associated with neurotoxic effects in patients with renal impairment, current evidence consists of very low-quality studies with conflicting findings. Clinicians may consider using either morphine or hydromorphone in mild-to-moderate renal impairment, while closely monitoring for neurotoxic effects, particularly when used in high doses and for extended duration.

23 keywords...

hide…